Cystic Fibrosis
📧 Sign up to get email alerts when something new happens for Cystic Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: A Study Evaluating the Long-term Safety of VX-445 Combination Therapy [Phase 3]
A Phase 3 study assessing the long-term safety of VX-445 combination therapy in cystic fibrosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years [Phase 3]
Phase 3 trial evaluating ELX/TEZ/IVA in children aged 2 through 5 years with cystic fibrosis has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 [Phase 2]
Phase 2 study of ABBV-3067 alone and with ABBV-2222 in cystic fibrosis completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Cystic Fibrosis - Insulin Deficiency, Early Action [Phase 3]
Phase 3 clinical trial update for cystic fibrosis exploring early insulin deficiency action; study completed.
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: ATCF (Azole Therapy in Cystic Fibrosis) [Phase 2]
Phase 2 clinical trial of azole therapy in cystic fibrosis patients with Aspergillus infections has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 [Phase 2]
Phase 2 clinical trial evaluating gut imaging for function and transit in cystic fibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2023-05-22Clinical Trial Update: Pilocarpine Microneedles for Sweat Induction (PMN-SI) [NA]
Completed clinical trial evaluating pilocarpine microneedles for sweat induction in cystic fibrosis patients; results posted in 2023.
-
FDA approval · 2023-05-03FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for KALYDECO (ivacaftor) from Vertex Pharmaceuticals Incorporated. The approval approves changes…
-
FDA approval · 2023-05-03FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for KALYDECO (ivacaftor) submitted by Vertex Pharmaceuticals Incorporated.
-
FDA approval · 2023-04-26FDA Approved: TRIKAFTA — Original Application (Vertex Pharmaceuticals Incorporated)
The FDA approved TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) as an original application for cystic fibrosis, representing a pivotal triple-c…
-
FDA approval · 2023-04-26FDA Approved: TRIKAFTA — Supplemental Application (Vertex Pharmaceuticals Incorporated)
FDA approves a supplemental application for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) from Vertex Pharmaceuticals Incorporated.
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis [Phase 2]
Phase 2 trial evaluating VX-121 combination therapy for cystic fibrosis has completed with posted results.
-
FDA approval · 2023-04-10FDA Approved: TOBRAMYCIN INHALATION SOLUTION PAK — Supplemental Application (Genericus, Inc.)
FDA approved a supplemental application to Genericus, Inc. for TOBRAMYCIN INHALATION SOLUTION PAK, a generic version of tobramycin inhalatio…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects [Phase 1, Phase 2]
Phase 1 and Phase 2 clinical trial update for inhaled AR-501 in healthy adults and Pseudomonas aeruginosa-infected cystic fibrosis subjects;…
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) [Phase 1, Phase 2]
Phase 1/2 clinical trial update for a bacteriophage therapy targeting cystic fibrosis conducted at Yale (CYPHY) with completed status and po…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD [NA]
A terminated clinical trial evaluating bright light therapy for depressive symptoms in adults with cystic fibrosis and related conditions, w…
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients [Phase 3]
A Phase 3 trial evaluating tobramycin delivered via nebulized sonic aerosol for chronic rhinosinusitis in cystic fibrosis patients was termi…
-
FDA approval · 2023-02-10FDA Approved: TOBRAMYCIN INHALATION SOLUTION PAK — Supplemental Application (Genericus, Inc.)
The FDA approved a supplemental application for Tobramycin Inhalation Solution PAK from Genericus, Inc., enabling its marketing as a supplem…
-
FDA approval · 2023-02-10FDA Approved: TOBI — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for TOBI (tobramycin) submitted by Viatris Specialty LLC.
-
FDA approval · 2023-02-10FDA Approved: TOBI PODHALER — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for TOBI Podhaler (tobramycin) submitted by Viatris Specialty LLC.
-
FDA approval · 2023-02-10FDA Approved: TOBRAMYCIN INHALATION — Supplemental Application (Prasco, LLC)
The FDA approved a supplemental application from Prasco, LLC for Tobramycin Inhalation, authorizing a supplemental approval of a generic inh…
-
CLINICAL_TRIALS trial_result · 2023-01-30Clinical Trial Update: Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis [Phase 1]
Phase 1 safety and tolerability study of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis [Phase 2]
Phase 2 trial evaluating lenabasum for cystic fibrosis has completed; results were posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-01-06Clinical Trial Update: Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del [Phase 3]
Phase 3 safety and pharmacokinetic study of lumacaftor/ivacaftor in children aged 1 to under 2 years with cystic fibrosis (homozygous F508de…
-
CLINICAL_TRIALS trial_result · 2022-11-22Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele [Phase 2]
Phase 2 study assessing ELX-02 in cystic fibrosis patients with the G542X allele has completed.